Injectable dual-scale mesoporous silica cancer vaccine enabling efficient delivery of antigen/adjuvant-loaded nanoparticles to dendritic cells recruited in local macroporous scaffold

Nguyen, Thanh Loc; Geun, Bong; Choi, Youngjin; Im, Jae Hyeng; Kim, Jaeyun

doi:10.1016/j.biomaterials.2020.119859

Cited by 85 publications

(56 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is not only siRNAs that are delivered to DCs; plasmid DNA carried by mannosylated liposomes can also be useful to encode specific modulators and is able to generate tumor-specific cytotoxic T lymphocytes by DC mediation, providing a high anti-metastatic potential [ 110 ]. Thus, studies corroborate the idea that the construction of nanovaccines against cancer has the potential to promote the maturation of DCs, since after phagocytosis, they released antigens in a controlled manner, leading to an increased cellular and humoral immune response [ 111 , 150 , 151 , 152 ].…”

Section: 2 Dendritic Cells (Dc)supporting

confidence: 55%

Nanocarriers Used in Drug Delivery to Enhance Immune System in Cancer Therapy

et al. 2021

View full text Add to dashboard Cite

Cancer, a group of diseases responsible for the second largest cause of global death, is considered one of the main public health problems today. Despite the advances, there are still difficulties in the development of more efficient cancer therapies and fewer adverse effects for the patients. In this context, nanobiotechnology, a materials science on a nanometric scale specified for biology, has been developing and acquiring prominence for the synthesis of nanocarriers that provide a wide surface area in relation to volume, better drug delivery, and a maximization of therapeutic efficiency. Among these carriers, the ones that stand out are those focused on the activation of the immune system. The literature demonstrates the importance of this system for anticancer therapy, given that the best treatment for this disease also activates the immune system to recognize, track, and destroy all remaining tumor cells.

show abstract

Section: 2 Dendritic Cells (Dc)supporting

confidence: 55%

Nanocarriers Used in Drug Delivery to Enhance Immune System in Cancer Therapy

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Despite MSNs use as widespread vehicles for cancer vaccinations, mesoporous silica rods (MSRs) recruited APCs in local macroporous scaffolds to induce robust immune activation and antigen-specific adaptive immunity 147 . MSR-MSNs dual-scale vaccines consist of MSNs and MSRs 148 , both of which are internalized by DCs and recruit DCs by virtue of their larger space. This process reverses the immunosuppressive pathway and educates immune cells to combat cancer.…”

Section: Inorganic-based Vehiclesmentioning

confidence: 99%

Nanomaterial-based delivery vehicles for therapeutic cancer vaccine development

Liang

Zhao

2021

Cancer Biol. Med.

View full text Add to dashboard Cite

Nanomaterial-based delivery vehicles such as lipid-based, polymer-based, inorganics-based, and bio-inspired vehicles often carry distinct and attractive advantages in the development of therapeutic cancer vaccines. Based on various delivery vehicles, specifically designed nanomaterials-based vaccines are highly advantageous in boosting therapeutic and prophylactic antitumor immunities. Specifically, therapeutic vaccines featuring unique properties have made major contributions to the enhancement of antigen immunogenicity, encapsulation efficiency, biocompatibility, and stability, as well as promoting antigen cross-presentation and specific CD8 + T cell responses. However, for clinical applications, tumor-associated antigen-derived vaccines could be an obstacle, involving immune tolerance and deficiency of tumor specificities, in achieving maximum therapeutic indices. However, when using bioinformatics predictions with emerging innovations of in silico tools, neoantigen-based therapeutic vaccines might become potent personalized vaccines for tumor treatments. In this review, we summarize the development of preclinical therapeutic cancer vaccines and the advancements of nanomaterial-based delivery vehicles for cancer immunotherapies, which provide the basis for a personalized vaccine delivery platform. Moreover, we review the existing challenges and future perspectives of nanomaterial-based personalized vaccines for novel tumor immunotherapies.

show abstract

“…Efforts have also been made to generate nanoparticles that are able to carry multiple immunostimulatory agents. Nguyen and coworkers [56] fabricated a dual-scale cancer vaccine which is composed of ovalbumin-and CpG ODN-loaded mesoporous silica nanoparticles and mesoporous silica microrods that were incorporated with granulocyte-macrophage colony-stimulating factor (GM-CSF, a DC-recruiting chemokine). It was shown that this hybrid vaccine significantly inhibits melanoma growth and a combination therapy of this vaccine with an immune checkpoint inhibitor produces a synergistic effect against tumor growth [56].…”

Section: Emerging Nanoparticle-based Systems For Cancer Immunotherapymentioning

confidence: 99%

Emerging nanomedicines for effective breast cancer immunotherapy

2020

View full text Add to dashboard Cite

Breast cancer continues to be the most frequently diagnosed malignancy among women, putting their life in jeopardy. Cancer immunotherapy is a novel approach with the ability to boost the host immune system to recognize and eradicate cancer cells with high selectivity. As a promising treatment, immunotherapy can not only eliminate the primary tumors, but also be proven to be effective in impeding metastasis and recurrence. However, the clinical application of cancer immunotherapy has faced some limitations including generating weak immune responses due to inadequate delivery of immunostimulants to the immune cells as well as uncontrolled modulation of immune system, which can give rise to autoimmunity and nonspecific inflammation. Growing evidence has suggested that nanotechnology may meet the needs of current cancer immunotherapy. Advanced biomaterials such as nanoparticles afford a unique opportunity to maximize the efficiency of immunotherapy and significantly diminish their toxic side-effects. Here we discuss recent advancements that have been made in nanoparticle-involving breast cancer immunotherapy, varying from direct activation of immune systems through the delivery of tumor antigens and adjuvants to immune cells to altering immunosuppression of tumor environment and combination with other conventional therapies.

show abstract

Injectable dual-scale mesoporous silica cancer vaccine enabling efficient delivery of antigen/adjuvant-loaded nanoparticles to dendritic cells recruited in local macroporous scaffold

Cited by 85 publications

References 31 publications

Nanocarriers Used in Drug Delivery to Enhance Immune System in Cancer Therapy

Nanocarriers Used in Drug Delivery to Enhance Immune System in Cancer Therapy

Nanomaterial-based delivery vehicles for therapeutic cancer vaccine development

Emerging nanomedicines for effective breast cancer immunotherapy

Contact Info

Product

Resources

About